Dorothee Pflueger

Title: Dorothee Pflueger: Innovator in Prostate Cancer Research

Introduction

Dorothee Pflueger is a prominent inventor based in Zurich, Switzerland. She has made significant contributions to the field of cancer research, particularly in the diagnosis and treatment of prostate cancer. With a total of 2 patents, her work has the potential to impact the lives of many patients.

Latest Patents

Pflueger's latest patents focus on innovative compositions and methods for diagnosing prostate cancer. One of her patents describes RNA transcripts representing a fusion of human SLC45A3 nucleic acid and human ELK4 nucleic acid, which are associated with prostate cancer. This invention provides compositions and methods useful for detecting these fusion transcripts, which can be instrumental in cancer therapy. Another significant patent details methods of diagnosing and treating prostate cancer characterized by the NDRG1-ERG fusion. This discovery arose from an in-depth analysis of prostate cancer samples, leading to the identification of a novel gene translocation between the NDRG1 gene and the ERG oncogene.

Career Highlights

Dorothee Pflueger is affiliated with Cornell University, where she continues her research and innovation in cancer diagnostics. Her work is recognized for its potential to enhance the understanding and treatment of prostate cancer.

Collaborations

Pflueger has collaborated with notable researchers in her field, including Mark A. Rubin and David S. Rickman. These collaborations have further enriched her research and contributed to the advancement of cancer diagnostics.

Conclusion

Dorothee Pflueger's innovative work in prostate cancer research exemplifies the impact of dedicated inventors in the medical field. Her patents and collaborations highlight her commitment to improving cancer diagnosis and treatment.